Merck & Co. logo
Merck & Co. MRK
$ 116.23 1.8%

Annual report 2025
added 02-24-2026

report update icon

Merck & Co. Gross Profit 2011-2026 | MRK

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Merck & Co.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - - 32.7 B 28.8 B 27.3 B 25.9 B 24.6 B 25.5 B 27.1 B 30.8 B 31.2 B

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
32.7 B 24.6 B 28.2 B

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Grifols, S.A. Grifols, S.A.
GRFS
2.79 B $ 7.71 1.65 % $ 6.83 B spainSpain
Altimmune Altimmune
ALT
8.18 K $ 3.5 4.64 % $ 308 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
5.51 M - 2.54 % $ 160 B franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
625 M $ 221.52 -0.16 % $ 5 B danmarkDanmark
Heron Therapeutics Heron Therapeutics
HRTX
114 M $ 0.8 2.5 % $ 133 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
4.73 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
102 K - -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
2.32 M - - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
90 K - -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
Incyte Corporation Incyte Corporation
INCY
2.04 B $ 90.82 0.04 % $ 17.7 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
14 M - -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
4.67 B - 0.49 % $ 251 B cayman-islandsCayman-islands
InMed Pharmaceuticals InMed Pharmaceuticals
INM
1.4 M $ 0.79 -3.52 % $ 1.93 M canadaCanada
INmune Bio INmune Bio
INMB
-10.9 K $ 1.23 5.13 % $ 22.1 M usaUSA
Inovio Pharmaceuticals Inovio Pharmaceuticals
INO
40.6 M $ 1.57 -0.95 % $ 34.8 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
23.8 M $ 1.34 14.26 % $ 235 M franceFrance
ChemoCentryx ChemoCentryx
CCXI
64.9 M - - $ 3.74 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
1.07 - - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
123 M - -7.23 % $ 13 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
-10.6 M - - $ 867 M germanyGermany
Compugen Ltd. Compugen Ltd.
CGEN
63.5 M $ 2.13 1.91 % $ 199 M israelIsrael
CorMedix CorMedix
CRMD
276 M $ 6.35 1.6 % $ 457 K usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-40.6 M $ 4.33 2.12 % $ 719 M canadaCanada
Kamada Ltd. Kamada Ltd.
KMDA
76.4 M $ 8.33 0.97 % $ 260 M israelIsrael